Harnessing the body’s immune system

The growing understanding of tumor cells’ ability to evade immune surveillance has led to advances in the field of immuno‑oncology.1 Malignant cells manipulate a variety of physiological mechanisms involved in antigenicity, immune activation, T‑cell priming and recruitment, and upregulation of checkpoint molecules.1 Many of these mechanisms may be impacted simultaneously to promote tumor cell survival.1 Immunotherapies harness the body’s own immune system to fight cancer by using different immunological pathways to enhance antitumor responses.1,2 GSK is exploring different clinical assets aimed at augmenting the immune response, reducing immune suppression, and modulating the tumor microenvironment.3,4